A 12-month post-treatment threshold effectively differentiates early from late progression in CLL, impacting survival outcomes significantly. Early progression within 12 months post-treatment ...
Two-third of those who receive a chronic lymphocytic leukemia (CLL) diagnosis are age 65 or older, so the ease with which drugs are covered in Medicare has an outsized role in patient access to care.
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie, in collaboration with Hoffmann-La Roche and the German CLL Study Group, has completed a Phase III clinical trial titled ‘A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results